C4 Therapeutics
CCCC
92 hedge funds and large institutions have $267M invested in C4 Therapeutics in 2023 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 28 increasing their positions, 24 reducing their positions, and 22 closing their positions.
314% more capital invested
Capital invested by funds: $64.5M → $267M (+$202M)
41% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 22
25.61% more ownership
Funds ownership: 70.18% → 95.79% (+26%)
17% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 24
15% more call options, than puts
Call options by funds: $7.75M | Put options by funds: $6.76M
11% more funds holding
Funds holding: 83 → 92 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$11.1M |
| 2 |
CC
Commodore Capital
New York
|
+$8.66M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$4.82M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.44M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$3.7M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2.15M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.95M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.86M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.74M |
CCCC Hedge Fund Activity: Q4 2023 in Review
92 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q4 2023, worth a combined $267M — up 314% from $64.5M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CCCC positions and 22 closed out — a net gain of 9 holders — while 28 added to existing stakes and 24 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $11.1M. The largest seller was Aquilo Capital Management, exiting entirely with an estimated $3.7M sold.
- 92 institutional investors held C4 Therapeutics (CCCC) as of Q4 2023, up from 83 in Q3 2023.
- Funds reported $267M of C4 Therapeutics stock for Q4 2023, up 314% quarter-over-quarter.
- 31 funds opened new C4 Therapeutics positions in Q4 2023 and 22 closed out, a net change of +9 holders.
- The largest C4 Therapeutics buyer in Q4 2023 was RA Capital Management, an estimated $11.1M added.
- The largest C4 Therapeutics seller in Q4 2023 was Aquilo Capital Management, an estimated $3.7M sold.
Based on aggregated 13F filings for Q4 2023.